Non-small Cell Lung Cancer (NSCLC) — Expanded Access Programs
Overview
Right2Hope maintains a directory of 36 expanded access programs, clinical trials, and compassionate use pathways listed for Non-small Cell Lung Cancer (NSCLC). Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with non-small cell lung cancer (nsclc) programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 16 programs are currently active or recruiting, with the remaining 20 in other lifecycle stages. Sponsors actively running programs in this area include AstraZeneca, Revolution Medicines, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme LLC, AbbVie, and others.
By recruiting status
Snapshot of where every Non-small Cell Lung Cancer (NSCLC) program currently sits in its lifecycle.
- Active / Recruiting16
- Inactive20
Top sponsors
Organisations running the most Non-small Cell Lung Cancer (NSCLC) programs in the directory.
- AstraZeneca5 programs
- Revolution Medicines, Inc.4 programs
- Bristol-Myers Squibb3 programs
- Merck Sharp & Dohme LLC3 programs
- AbbVie1 program
- Agenus Inc.1 program
- Amgen1 program
- Astellas Pharma Global Development, Inc.1 program
- Duke University1 program
- EMD Serono Research & Development Institute, Inc.1 program
Non-small Cell Lung Cancer (NSCLC) programs (36)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Comparing Setidegrasib (ASP3082) and Docetaxel for Non-small Cell Lung Cancer with KRAS G12D Mutation — Astellas Pharma Global Development, Inc.
- Study Comparing Pumitamig and Durvalumab After Chemoradiation in Patients with Unremovable Stage III Non-small Cell Lung Cancer — Bristol-Myers Squibb
- Study Comparing Pumitamig and Pembrolizumab for Untreated Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels — Bristol-Myers Squibb
- Study on the Safety and Effectiveness of BMS-986523 Alone and with Other Cancer Treatments for Advanced Solid Tumors — Bristol-Myers Squibb
- Phase 3 Study of Taletrectinib vs Placebo as an Additional Treatment in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) — Nuvation Bio Inc.
- Phase III Study Comparing Datopotamab Deruxtecan and Docetaxel for Advanced TROP2-positive Non-squamous Lung Cancer — AstraZeneca
- Study on Anti-CEACAM5 ADC M9140 for Advanced Solid Tumors (PROCEADE PanTumor) — EMD Serono Research & Development Institute, Inc.
- Study on Durvalumab and Tremelimumab with Chemotherapy or Chemotherapy Alone for Lung Cancer Patients (POSEIDON) — AstraZeneca
- Study on Durvalumab with Olaparib or Alone After Initial Treatment in Lung Cancer Patients (ORION) — AstraZeneca
- Study on Elironrasib and Daraxonrasib for Advanced KRAS G12C Mutant Solid Tumors — Revolution Medicines, Inc.
- Study on First-In-Human Use of STX-241 for Advanced or Metastatic Lung Cancer Resistant to EGFR Treatments — Pierre Fabre Medicament
- Study on Osimertinib and Targeted Radiation for EGFR Mutant Non-Small Cell Lung Cancer — University of Texas Southwestern Medical Center
- Study on RAS(ON) Inhibitors with Ivonescimab for Patients with Solid Tumors — Revolution Medicines, Inc.
- Study on RMC-6236 for Patients with Advanced Solid Tumors with Specific RAS Mutations — Revolution Medicines, Inc.
- Study on GTAEXS617 for Adults with Advanced Solid Tumors — Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Study on IMM-1-104 for Patients with Previously Treated Advanced or Metastatic Solid Tumors with RAS Mutation — Immuneering Corporation
- Study on AZD0022 for Treating Tumors with KRASG12D Mutation in Adults — AstraZeneca
- Study Comparing Sotorasib with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer — Amgen
- Study on TAK-186 (MVC-101) for Adults with Advanced or Metastatic Cancer — Takeda
- Study on Tiragolumab and Atezolizumab Compared to Placebo and Atezolizumab in Patients with Completely Removed Non-Small Cell Lung Cancer After Chemotherapy — Hoffmann-La Roche
- A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations — AstraZeneca
- Study on the Safety and Effects of IDE574 Therapy in Adults with Advanced Solid Tumors — IDEAYA Biosciences
- Program to Access Botensilimab and Balstilimab Before Official Approval — Agenus Inc.
- Expanded Access to Telisotuzumab Vedotin — AbbVie
- Study on GEN1042 Safety and Anti-Tumor Effects in Patients with Advanced Solid Tumors — Genmab
- Access Programs for LDK378, Ceritinib — Novartis Pharmaceuticals
- Study on Inhaled Azacytidine with Chemotherapy and Immunotherapy for Treating Early-Stage Non-Small Cell Lung Cancer — National Cancer Institute (NCI)
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Duke University
- Study on Pembrolizumab for Advanced Non-Small Cell Lung Cancer (NSCLC) with Performance Status 2-3 — Icahn School of Medicine at Mount Sinai
- Study on Immunotherapy Combinations for Advanced Non-Small Cell Lung Cancer (NSCLC) — Servier Bio-Innovation LLC
- Study on Sacituzumab Tirumotecan and Pembrolizumab Combination Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer with High PD-L1 Levels — Merck Sharp & Dohme LLC
- Study Comparing Sacituzumab Tirumotecan to Chemotherapy in Previously Treated Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations or Other Genetic Changes — Merck Sharp & Dohme LLC
- Study Comparing Sacituzumab Tirumotecan with Pemetrexed and Carboplatin for Advanced Non-Small Cell Lung Cancer with EGFR Mutation — Merck Sharp & Dohme LLC
- Study on New RAS(ON) Inhibitor Combinations for Patients with Advanced RAS-Mutated Non-Small Cell Lung Cancer — Revolution Medicines, Inc.
- Study on the Immune Response of MUC1 Peptide Vaccine for Non-Small Cell Lung Cancer — Olivera Finn
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Non-small Cell Lung Cancer (NSCLC) to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.